Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine

Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. 11, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that the company will report top-line results from the Phase 3 Allovectin® Immunotherapy for Metastatic Melanoma (AIMM) trial before the opening of trading on Monday, August 12, and conduct a conference call and webcast to discuss the results at 8:00 a.m. GEN-003 is comprised of HSV-2 glycoprotein D2 (gD2ΔTMR340-363) and a truncated form of infected cell polypeptide 4 (ICP4383-766), formulated with Matrix M-2 (MM-2) adjuvant (GEN-003/MM-2). What matters more than the call are the price targets and the inferences made in the research calls. I wouldn’t think herpes natural suppression of saying good-by. If all the funds raised for cancer research study were devoted to putting this basic therapy in the hands of every man and woman on earth, we might not only mark out cancer completely but also have a world that is devoid of disease. Vijay Samant; Vical’s Vice President of Vaccine Research, Dr.

General practitioners are able to prescribe oral antivirals for suppressing herpes. This technology from Vical can be used in infectious disease vaccines, cancer vaccines, and cardiovascular disorders. Vical will conduct a conference call and webcast on Friday, July 15, at 8:00 a.m. CMV infection rates are high worldwide; the CMV seroprevalence rate in the U.S. While a vaccination/cure for herpes is being checked by several business, absolutely nothing has actually achieved success since yet. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 457-2643 (preferred), or (888) 503-8163 (toll-free), and reference confirmation code 6648633. Samant was a member of the Board of Directors for Raptor Pharmaceutical from 2011 to 2014, and was a member of the Board of Directors for BioMarin Pharmaceutical from 2002 to 2004.

Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine
Additional information on Vical is available at www.vical.com. The study is expected to be completed by the end of 2016. A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. TransVax™ is a bivalent DNA vaccine containing plasmids (closed loops of DNA) encoding CMV pp65 and gB antigens for induction of both cellular and humoral immune responses. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2356 (preferred), or (888) 318-7469 (toll-free), and reference confirmation code 3419348. The company expects the trial to enlist quickly, given the overwhelming interest in the program. CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries.

While a healthy immune system typically protects an infected person against CMV disease, it rarely succeeds in eliminating the infection, and those whose immune systems are not fully functional are at high risk of CMV reactivation, potentially leading to severe illness or death. The company announced the online publication of Baxter’s (Baxter International Inc.) preclinical evaluations of Vical’s Vaxfectin® adjuvant in combination with Baxter’s seasonal and pandemic influenza vaccines. The results of these clinical trials demonstrate the need to improve protection, which may require changes in dosing schemes, adjuvant optimization, and the addition of other antigenic targets capable of inducing antigen-specific CD4+ and CD8+ T cell populations. (NASDAQ: SNSS), and Vical Incorporated (NASDAQ: VICL) are just some of the companies reacting to ASCO and oncology news this morning. I’ve took the last o’ that there physic, herpes remove doctor. The organization is committed to becoming a global category leader by rapidly establishing a business model in urology, immunology & infectious diseases, oncology, neuroscience, DM complications & metabolic diseases. We currently anticipate that are available cash and investments are adequate to fund our activities into 2017.

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. I would also like to recommend Theodore Cohen’s recent Seeking Alpha article on Vical. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com. Smith, Ph.D., joined us as Executive Director, Vaccinology in September 2003, and was named Vice President, Vaccine Research in October 2006.

Forward-looking statements include statements about Vical’s technologies, the TransVax™ CMV vaccine, as well as the company’s focus, licensees, and independent and partnered product candidates. If they’re even close to accurate, Vical’s market cap will become much larger than the current $380 million or so. Clin Vaccine Immunol 2008; 15 1214-1221. The companies disclaim, however, any intent or obligation to update these forward-looking statements.

You may also like